Dante Labs Launching COVID-19 Testing in Europe Utilizing Fluidigm Pathogen Detection Kit on Biomark HD Platform
November 02 2020 - 8:30AM
Fluidigm Corporation (Nasdaq:FLDM), an innovative
biotechnology tools provider with a vision to improve life through
comprehensive health insight, today announced that Dante Labs, a
global pioneer in direct-to-consumer genomic testing, will be
offering saliva-based COVID-19 testing services in local
communities across Europe utilizing a Fluidigm® assay and reagents
designed to be run on the Fluidigm Biomark™ HD system.
“In our whole genome sequencing business, we discovered that
noninvasive saliva sample collection was very powerful in providing
a positive user experience for people worldwide, maximizing
access to advanced diagnostics and testing technologies,” said
Andrea Riposati, CEO of Dante Labs. “Because we believe advanced
saliva-based tests will be a crucial weapon against COVID-19,
we plan to utilize a Fluidigm saliva-based assay and microfluidics
technology for all of our saliva-based COVID-19 testing in
Europe.
“Exceptional reliability, high performance and the capacity of
the Biomark HD system to deliver at scale were all factors in
choosing Fluidigm. We are initially using the Fluidigm system to
test our own employees, followed by rollout of saliva-based
COVID-19 testing services in seven European countries, including
the United Kingdom, Italy, Spain and France. By the end of
November, we expect to be processing at least 30,000 saliva-based
COVID-19 tests per week in Europe.”
Saliva-based COVID-19 testing utilizing the high-throughput
Biomark HD system features an integrated testing platform and a
reliable supply chain that laboratories can combine with commonly
available automation platforms.
“With some nations in Europe seeing new records in daily
COVID-19 cases, we are honored to have been chosen by Dante Labs to
increase critically needed saliva-based COVID-19 testing capacity,”
said Chris Linthwaite, Fluidigm President and CEO. “In addition to
growing adoption of our technology for COVID-19 testing for large
public health, governmental and academic customers in the United
States, customers in other regions of the globe are embracing
Fluidigm microfluidics for high-throughput screening, which is
particularly important in countries where infection rates are
growing rapidly.”
About FluidigmFluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF® and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.
Fluidigm, the Fluidigm logo, Biomark, and CyTOF are
trademarks and/or registered trademarks of Fluidigm
Corporation in the United States and/or other
countries. All other trademarks are the sole property of their
respective owners. Fluidigm products are provided for Research
Use Only. Not for use in diagnostic procedures.
Fluidigm’s ongoing collaboration with the Defense Advanced
Research Projects Agency (DARPA) and its Epigenetic
CHaracterization and Observation (ECHO) program includes financial
support for development of innovative programs based on our
microfluidics technology.
About Dante LabsDante Labs’
mission is to make the most advanced genomic technologies
accessible to everyone. To date, it has customers in more than 95
countries who have personally experienced the power of the whole
genome. Dante Labs is also a global provider of COVID-19 testing
solutions for governments, businesses and individuals to help
people get back safely to normal life. To learn more or to purchase
a Dante Labs whole genome sequencing or COVID-19 test,
visit www.dantelabs.com and follow
@DanteLabs.Forward-Looking Statements for
FluidigmThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, among others, statements regarding
the anticipated benefits of a commercial program to facilitate
distribution of Fluidigm’s COVID-19 tests. Forward-looking
statements are subject to numerous risks and uncertainties that
could cause actual results to differ materially from currently
anticipated results, including but not limited to risks relating to
the potential adverse effects of the coronavirus pandemic on our
business and operating results during 2020; uncertainties in
contractual relationships; our ability and/or the ability of the
research institutions utilizing our products and technology to
obtain and maintain Emergency Use Authorization from the FDA and
any other requisite approvals to use our products and technology
for diagnostic testing purposes; potential changes in priorities or
requirements for Emergency Use Authorizations; potential
limitations of any Emergency Use Authorization; potential changes
in the priorities of government agencies; challenges inherent in
developing, manufacturing, launching, marketing, and selling new
products; risks relating to company research and development and
distribution plans and capabilities; interruptions or delays in the
supply of components or materials for, or manufacturing of,
Fluidigm products; potential product performance and quality
issues; intellectual property risks; and competition. Information
on these and additional risks and uncertainties and other
information affecting Fluidigm business and operating
results is contained in Fluidigm’s Annual Report on Form 10-K for
the year ended December 31, 2019, and in its other filings
with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date
hereof. Fluidigm disclaims any obligation to update these
forward-looking statements except as may be required by law.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and webcasts.
Fluidigm
Media:Mark SpearmanSenior Director, Corporate Communications650
243 6621
mark.spearman@fluidigm.com
Investors:Agnes LeeVice President, Investor Relations650 416
7423
agnes.lee@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024